Association between the haemoglobin glycation index (HGI) and clinical outcomes in patients with acute decompensated heart failure

Ann Med. 2024 Dec;56(1):2330615. doi: 10.1080/07853890.2024.2330615. Epub 2024 Mar 21.

Abstract

Background: A growing number of studies show that people with similar blood glucose levels have different levels of glycosylated haemoglobin (HbA1c), and relying only on HbA1c may lead to clinical decision-making errors. The haemoglobin glycation index (HGI) quantifies the difference in HbA1c among individuals and is strongly linked to the risk of cardiovascular disease. However, the connection between this phenomenon and the poor outcomes of patients with acute decompensated heart failure (ADHF) is currently unknown.

Patients and methods: This retrospective, single-centre-based cohort study included 1531 hospitalized patients with ADHF from September 2010 to January 2020. The HGI is calculated from the difference between the observed and predicted HbA1c values [predicted HbA1c = 0.024 × fasting plasma glucose (FPG) (mg/dL)+3.1]. The endpoints examined in the study included all-cause death, cardiovascular (CV) death, and major adverse cardiac events (MACE). We fitted multivariable-adjusted Cox proportional hazard models to investigate the association between the HGI and clinical outcomes.

Results: During the five-year follow-up, 427 (27.9%) patients died from all causes, 232 (15.6%) from CV death, and 848 (55.4%) from MACE. The restricted cubic spline analysis also showed that the cumulative risk of all-cause and CV deaths decreased linearly with increasing HGI. According to multivariate Cox proportional hazard models, the highest tertile of the HGI was associated with a lower incidence of all-cause and cardiovascular deaths [all-cause death, adjusted hazard ratio (HR): 0.720, 95% confidence interval (CI): 0.563-0.921, p = 0.009; CV death, adjusted HR: 0.619, 95% CI: 0.445-0.861, p = 0.004]. A 1% increase in the HGI was associated with a 12.5% reduction in the risk of all-cause death and a 20.8% reduction in the risk of CV death.

Conclusions: A high HGI was directly associated with a reduction in all-cause and CV deaths but was not associated with MACE. These findings may be helpful in the management of patients with ADHF.

Keywords: Haemoglobin glycation index; acute decompensated heart failure; all-cause death; cardiovascular death; diabetes; major adverse cardiac events.

Plain language summary

Recent studies have demonstrated that significant discrepancies between HbA1c and actual blood glucose levels may lead to clinical decision-making errors.The inconsistency of previous research results suggests that the HGI may have different predictive ability in populations with different diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose / analysis
  • Cohort Studies
  • Diabetes Mellitus, Type 2* / complications
  • Glycated Hemoglobin
  • Heart Failure* / complications
  • Heart Failure* / epidemiology
  • Hemoglobins / analysis
  • Humans
  • Maillard Reaction
  • Retrospective Studies

Substances

  • Glycated Hemoglobin
  • Hemoglobins
  • Blood Glucose

Grants and funding

This work was funded by the Medical Science and Technology Development Foundation, Nanjing Department of Health [YKK19063 to Zhonghai Wei]; Jiansu Provincial Key Research and Development Foundation [BE2022665 to Zhonghai Wei]; Nanjing Medical Science and Technique Development Foundation [QRX17114 to Han Wu]; and Natural Science Foundation of China [81970296 to Han Wu].